In HepG2 cells, 0.1–1 μM 17-OHP increased GR reporter activity after 24 hours. Receptor-domain deletion abolished this response. In mouse primary hepatocytes, RU486 suppressed 17-OHP-induced GR target-gene expression; tested alternative nuclear-receptor reporters were not activated. [1]
GR coactivator recruitment
Biochemical assay · Cell-free human recombinant GR ligand-binding domain and fluorescent coactivator peptide [1]
17-OHP promoted GR coactivator recruitment; this functional EC50 is not an equilibrium binding constant.
Literature-Reported Treatment Conditions
- Exposure duration
- 20 minutes
- Method
- LanthaScreen TR-FRET GR coactivator assay; dexamethasone comparator
- Reported limits
- Assay vehicle and number of independent FRET determinations are not specified in the relevant text/caption.
Methods and source locations
Compound reported in the paper: 17-Hydroxyprogesterone; Compound label in the paper: 17-OHP
Evidence applies to the named unesterified research compound, not caproate/acetate derivatives or validation of A15860 lots.
Figure 1I; Results: 17-OHP activates GR in hepatocytes; Methods: Ligand-binding analysis
GR ligand-binding-domain coactivator recruitment: Sigmoidal dose-response fit; reported in Results, not estimated from the curve. — Figure 1I and corresponding Results paragraph
Cellular validation of GR activation
Cell-based study · Human HepG2 reporter cells; mouse primary hepatocytes [1]
17-OHP increased GR reporter activity and GR target-gene expression. Loss of GR DNA- or ligand-binding domains abolished reporter activation; RU486 suppressed target-gene induction.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.1 and 1 μM 17-OHP in reporter and target-gene assays; 0.1 μM in localization/ChIP assays
- Exposure duration
- 24 hours for reporters; 16 hours for target-gene assays; 1 hour for localization and ChIP
- Method
- GRE/PEPCK luciferase reporters, qPCR, subcellular Western blot and GR ChIP
- Vehicle
- Ethanol control
- Co-treatment
- Figure 1F: 10 μM RU486 pretreatment for 2 hours, followed by 1 μM 17-OHP for 16 hours
- Reported limits
- Do not interpret plotted replicates as independent biological experiments; caption does not define that level of replication.
Methods and source locations
Compound reported in the paper: 17-Hydroxyprogesterone; Compound label in the paper: 17-OHP
Evidence applies to the named unesterified research compound, not caproate/acetate derivatives or validation of A15860 lots.
Figure 1A–H and caption; Methods: Cell culture, Luciferase reporter assays, RNA isolation and real-time qPCR, Western blots, ChIP; Supplemental Figure 1
GR transcriptional activation and target-gene induction: Renilla-normalized reporter assay; 36B4-normalized qPCR. RU486 also antagonizes PR; PR-expression controls are in Supplemental Figure 1E. — Figure 1A, B, D–F; Supplemental Figure 1E
Other nuclear-receptor responses under the tested conditions: Corresponding receptor/ligand positive controls are shown in Supplemental Figure 1A–D. This is a tested panel, not proof of universal selectivity. — Figure 1C; Supplemental Figure 1A–D